Lv6
1970 积分 2022-02-16 加入
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report
2天前
已完结
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF(V600E)-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
2天前
已完结
Effects of Radiotherapy in Normal Tissue
24天前
已完结
The promise of immunotherapy for central nervous system tumours
1个月前
已完结
A spatially resolved transcriptome landscape during thyroid cancer progression
2个月前
已完结
Glioma
3个月前
已完结
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3
5个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
5个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
5个月前
已完结
Characterization of 12 Unknown Photodegradation Impurities of Tunlametinib Capsules Using Liquid Chromatography Coupled With ion Trap/Time-Of-Flight Mass Spectrometry
6个月前
已完结
皖公网安备34019202002308
